The molecular neuroimaging of anxiety disorders

Current Psychiatry Reports

Volumn 6, Issue 4, 2004, Pages 274-279

  Talbot, Peter S ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR; DOPAMINE 2 RECEPTOR; HYDROCORTISONE; IMIPRAMINE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; BRAIN METABOLISM; BRAIN REGION; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; MOLECULAR MECHANICS; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA;

EID: 4444346827     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0077-x     Document Type: Review

References (69)

1. Talbot PS, Mathew SJ, Laruelle M: Brain imaging in depression and anxiety. In Handbook of Depression and Anxiety, edn 2. Edited by Kasper S, den Boer JA, Sitsen JM. New York: Marcel Dekker, Inc.; 2003:289-329.
2. Perani D, Colombo C, Bressi S, et al.: [18F] FDG PET study in obsessive-compulsive disorder: a clinical/metabolic correlation study after treatment. Br J Psychiatry 1995, 166:244-250.
3. Nordahl TE, Benkelfat C, Semple WE, et al.: Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989, 2:23-28.
4. Swedo SE, Schapiro MB, Grady CL, et al.: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 1989, 46:518-523.
5. Baxter LR Jr., Phelps ME, Mazziotta JC, et al.: Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987, 44:211-218.
6. Baxter LR Jr., Schwartz JM, Mazziotta JC, et al.: Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988, 145:1560-1563.
7. Adler CM, McDonough-Ryan P, Sax KW, et al.: fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. J Psychiatr Res 2000, 34:317-324.
8. McGuire PK, Bench CJ, Frith CD, et al.: Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994, 164:459-468.
9. Breiter HC, Rauch SL, Kwong KK, et al.: Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996, 53:595-606.
10. Rauch SL, Jenike MA, Alpert NM, et al.: Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994, 51:62-70.
11. Pujol J, Torres L, Deus J, et al.: Functional magnetic resonance imaging study of frontal lobe activation during word generation in obsessive-compulsive disorder. Biol Psychiatry 1999, 45:891-897.
12. Saxena S, Brody AL, Maidment KM, et al.: Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999, 21:683-693.
13. Brody AL, Saxena S, Schwartz JM, et al.: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998, 84:1-6.
14. Bartha R, Stein MB, Williamson PC, et al.: A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry 1998, 155:1584-1591.
15. Ebert D, Speck O, Konig A, et al.: 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res 1997, 74:173-176.
16. Fitzgerald KD, Moore GJ, Paulson LA, et al.: Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder. Biol Psychiatry 2000, 47:174-182.
17. Smith EA, Russell A, Lorch E, et al.: Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. Biol Psychiatry 2003, 54:1399-1405.
18. Kwon JS, Kim JJ, Lee DW, et al.: Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. Psychiatry Res 2003, 122:37-47.
19. Saxena S, Brody AL, Ho ML, et al.: Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003, 160:522-532.
20. Saxena S, Brody AL, Ho ML, et al.: Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002, 59:250-261.
21. Hansen ES, Hasselbalch S, Law I, Bolwig TG: The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 2002, 5:1-10.
22. Rosenberg DR, MacMaster FP, Keshavan MS, et al.: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000, 39:1096-1103.
23. Moore GJ, MacMaster FP, Stewart C, Rosenberg DR: Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998, 37:663-667.
24. Bolton J, Moore GJ, MacMillan S, et al.: Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry 2001, 40:903-906.
25. Benazon NR, Moore GJ, Rosenberg DR: Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. J Am Acad Child Adolesc Psychiatry 2003, 42:1279-1285.
26. Kang DH, Kwon JS, Kim JJ, et al.: Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 2003, 107:291-297.
27. Pogarell O, Hamann C, Popperl G, et al.: Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003, 54:1406-1413.
28. Simpson HB, Lombardo I, Slifstein M, et al.: Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry 2003, 54:1414-1421.
29. Wilson AA, Ginovart N, Schmidt M, et al.: Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000, 43:3103-3110.
30. Frankle WG, Huang Y, Hwang D-R, et al.: Comparative evaluation of serotonin transporter radioligands [11C]DASB and [1lC]McN 5652 in healthy humans. J Nucl Med 2004, 45:682-694.
31. Huang Y, Hwang DR, Narendran R, et al.: Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 2002, 22:1377-1398.
32. Bisaga A, Katz J, Antonini A, et al.: Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry 1998, 155:1178-1183.
33. Nordahl TE, Semple WE, Gross M, et al.: Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 1990, 3:261-272.
34. Nordahl TE, Stein MB, Benkelfat C, et al.: Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. Biol Psychiatry 1998, 44:998-1006.
35. De Cristofaro MT, Sessarego A, Pupi A, et al.: Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry 1993, 33:505-512.
36. Malizia AL, Cunningham VJ, Bell CJ, et al.: Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998, 55:715-720.
37. Kuikka J, Pitkanen A, Lepola U, et al.: Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl Med Commun 1995, 16:273-280.
38. Kaschka W, Feistel H, Ebert D: Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 1995, 29:427-434.
39. Bremner JD, Innis RB, White T, et al.: SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000, 47:96-106.
40. Brandt CA, Meller J, Keweloh L, et al.: Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. J Neural Transm 1998, 105:1325-1333.
41. Goddard AW, Mason GF, Almai A, et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001, 58:556-561.
42. Dager SR, Richards T, Strauss W, Artru A: Single-voxel 1H-MRS investigation of brain metabolic changes during lactate-induced panic. Psychiatry Res 1997, 76:89-99.
43. Dager SR, Friedman SD, Heide A, et al.: Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch Gen Psychiatry 1999, 56:70-77.
44. Dager SR, Marro KI, Richards TL, Metzger GD: Preliminary application of magnetic resonance spectroscopy to investigate lactate-induced panic. Am J Psychiatry 1994, 151:57-63.
45. Dager SR, Strauss WL, Marro KI, et al.: Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 1995, 152:666-672.
46. Neumeister A, Bain E, Nugent AC, et al.: Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004, 24:589-591.
47. Tauscher J, Bagby RM, Javanmard M, et al.: Inverse relationship between serotonin 5-HT1A receptor binding and anxiety: A [11C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 2001, 158:1326-1328.
48. Dewar KM, Stravynski A: The quest for biological correlates of social phobia: an interim assessment. Acta Psychiatr Scand 2001, 103:244-251.
49. Mathew SJ, Coplan JD, Gorman JM: Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001, 158:1558-1567.
50. Tiihonen J, Kuikka J, Bergstrom K, et al.: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997, 154:239-242.
51. Schneier FR, Liebowitz MR, Abi-Dargham A, et al.: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 2000, 157:457-459.
52. Breier A, Kestler L, Adler C, et al.: Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 1998, 155:1440-1442.
53. Kestler LP, Malhotra AK, Finch C, et al.: The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO Personality Inventory-Revised. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13:48-52.
54. Laakso A, Vilkman H, Kajander J, et al.: Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry 2000, 157:290-292.
55. Schneier FR, Liebowitz MR, Laruelle M: Detachment and generalized social phobia. Am J Psychiatry 2001, 158:327.
56. Laakso A, Wallius E, Kajander J, et al.: Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am J Psychiatry 2003, 160:904-910.
57. Kent J, Coplan JD, Lombardo I, et al.: Imaging the serotonin transporter in social phobia with (+)[C-11]McN5652. J Nucl Med 2000, 41:200P.
58. Kent JM, Coplan JD, Lombardo I, et al.: Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berl) 2002, 164:341-348.
59. Villareal G, King CY: Brain imaging in posttraumatic stress disorder. Semin Clin Neuropsychiatry 2001, 6:131-145.
60. Pitman RK, Shin LM, Rauch SL: Investigating the pathogenesis of posttraumatic stress disorder with neuroimaging. J Clin Psychiatry 2001, 62:47-54.
61. Sapolsky RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
62. De Bellis MD, Keshavan MS, Spencer S, Hall J: N-acetylaspartate concentration in the anterior cingulate of maltreated children and adolescents with PTSD. Am J Psychiatry 2000, 157:1175-1177.
63. Schuff N, Marmar CR, Weiss DS, et al.: Reduced hippocampal volume and N-acetyl aspartate in posttraumatic stress disorder. Ann N Y Acad Sci 1997, 821:516-520.
64. Schuff N, Neylan TC, Lenoci MA, et al.: Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder. Biol Psychiatry 2001, 50:952-959.
65. Freeman TW, Cardwell D, Karson CN, Komoroski RA: In vivo proton magnetic resonance spectroscopy of the medial temporal lobes of subjects with combat-related posttraumatic stress disorder. Magn Reson Med 1998, 40:66-71.
66. Brown S, Freeman T, Kimbrell T, et al.: In vivo proton magnetic resonance spectroscopy of the medial temporal lobes of former prisoners of war with and without posttraumatic stress disorder. J Neuropsychiatry Clin Neurosci 2003, 15:367-370.
67. Villarreal G, Petropoulos H, Hamilton DA, et al.: Proton magnetic resonance spectroscopy of the hippocampus and occipital white matter in PTSD: preliminary results. Can J Psychiatry 2002, 47:666-670.
68. Lim MK, Suh CH, Kim HJ, et al.: Fire-related post-traumatic stress disorder: brain 1H-MR spectroscopic findings. Korean J Radiol 2003, 4:79-84.
69. Neylan TC, Schuff N, Lenoci M, et al.: Cortisol levels are positively correlated with hippocampal N-acetylaspartate. Biol Psychiatry 2003, 54:1118-1121.